Treatment-resistant depression patients show both reduced glucocorticoid receptor function and a hyperactive hypothalamic-pituitary-adrenal axis. However, few studies have examined the role of the mineralocorticoid receptor. This study aimed to evaluate the functional activity of the mineralocorticoid receptor system in regulating the hypothalamic-pituitary-adrenal axis in well-defined treatment-resistant depression patients.
Material and method:
We recruited 24 subjects divided into: (a) treatment-resistant depression; (b) healthy controls. We evaluated: (a) the effect of combined glucocorticoid receptor/mineralocorticoid receptor stimulation with prednisolone; (b) the effect of prednisolone with the mineralocorticoid receptor antagonist spironolactone; and (c) the effect of spironolactone alone. The response of the hypothalamic-pituitary-adrenal axis was measured using salivary cortisol and plasma levels of drugs were also measured.
Results:
Treatment-resistant depression patients had higher cortisol compared with controls after all challenges. In controls, spironolactone increased cortisol compared to placebo. The co-administration of spironolactone with prednisolone in controls decreases the suppressive effects of prednisolone. In contrast, in treatment-resistant depression, spironolactone did not increase cortisol compared to placebo and spironolactone with prednisolone had no effect on the suppressive effects of prednisolone. Patients with treatment-resistant depression had a reduction in the conversation of spironolactone to the active metabolite canrenone.
Conclusion:
Our data confirmed that treatment-resistant depression is associated with hypercortisolism and these patients no longer show an hypothalamic-pituitary-adrenal response to the administration of a mineralocorticoid receptor antagonist, suggesting that there is a mineralocorticoid receptor malfunctioning, such as a down regulation, however, pharmacokinetics and pharmacodynamics in these subjects could also have had an effect on the lack of mineralocorticoid receptor response.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press.
2.
ArvatEMaccagnoBGiordanoR. (2001) Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. J Clin Endocrinol Metab86: 3176–3181.
3.
BardenNStecISMontkowskiA. (1997) Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology66: 212–220.
BeckATSteerRABallR. (1996) Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess67: 588–597.
6.
BifulcoABernazzaniOMoranPM. (2005) The childhood experience of care and abuse questionnaire (CECA.Q): validation in a community series. Br J Clin Psychol44: 563–581.
7.
BifulcoABrownGWHarrisTO (1994) Childhood Experience of Care and Abuse (CECA): a retrospective interview measure. J Child Psychol Psychiatry35: 1419–1435.
CornelisseSJoelsMSmeetsT (2011) A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory. Neuropsychopharmacology36: 2720–2728.
10.
De KloetERJoelsMHolsboerF (2005) Stress and the brain: from adaptation to disease. Nat Rev Neurosci6: 463–475.
11.
De KloetERVreugdenhilEOitzlMS. (1998) Brain corticosteroid receptor balance in health and disease. Endocr Rev19: 269–301.
12.
DeuschleMWeberBCollaM. (1998) Mineralocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans. Neuroendocrinology68: 355–360.
13.
DodtCKernWFehmHL. (1993) Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology58: 570–574.
14.
FirstMBSpitzerRLGibbonM. (1995) The Structured Clinical Interview for DSM-III-R Personality-Disorders (SCID-II) 2. Multisite test-retest reliability study. J Personal Disord9: 92–104.
15.
FirstMBSpitzerRLGibbonM. (1997) Structured Clinical Interview for DSM-IV Axis I Disorders- Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press.
16.
FloresBHKennaHKellerJ. (2006) Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology31: 628–636.
17.
GrossmannCFreudingerRMildenbergerS. (2004) Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption. Am J Physiol Renal Physiol286: F1226–F1231.
18.
GrottoliSGiordanoRMaccagnoB. (2002a) The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. J Clin Endocrinol Metab87: 4616–4620.
19.
GrottoliSMaccagnoBRamunniJ. (2002b) Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. J Endocrinol Invest25: 420–425.
20.
HalbreichUAsnisGMShindledeckerR. (1985) Cortisol secretion in endogenous depression. II. Time-related functions. Arch Gen Psychiatry42: 909–914.
21.
HeuserIDeuschleMWeberB. (2000) Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology25: 513–518.
22.
HolsboerF (1999) The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res33: 181–214.
23.
HolsboerF (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology23:477–501.
24.
JoelsMKarstHDeRijkR. (2008) The coming out of the brain mineralocorticoid receptor. Trends Neurosci31: 1–7.
25.
JuruenaMFCleareAJParianteCM (2004) The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev Bras Psiquiatr26: 189–201.
26.
JuruenaMFCleareAJPapadopoulosAS. (2006) Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology189: 225–235.
27.
JuruenaMParianteCPapadpoulosA. (2009) Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry194: 342–349.
28.
JuruenaM.FParianteCMPapadopoulosA. ( 2010a) The development and application of the prednisolone suppression test in psychiatry: a novel tool for assessing glucocorticoid and mineralocorticoid receptor function. Mind Brain1: 115–122.
29.
JuruenaMFCleareAJPapadopoulosAS. (2010b) The prednisolone suppression test in depression: dose–response and changes with antidepressant treatment. Psychoneuroendocrinology35: 1486–1491.
30.
KellnerMBakerDGYassouridisA. (2002) Mineralocorticoid receptor function in patients with posttraumatic stress disorder. Am J Psychiatry159: 1938–1940.
31.
KirschbaumCHellhammerDH (1994) Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology19: 313–333.
32.
KocarekTASchuetzEGStromSC. (1995) Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos23: 415–421.
33.
KuningasMDe RijkRHWestendorpRG. (2007) Mental performance in old age dependent on cortisol and genetic variance in the mineralocorticoid and glucocorticoid receptors. Neuropsychopharmacology32: 1295–1301.
34.
LembkeAGomezRTenakoonL. (2013) The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology38: 115–121.
35.
LopezJFChalmersDTLittleKY. (1998) A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry43: 547–573.
36.
McEwenBS (2000) Allostasis and allostatic load: Implications for neuropsychopharmacology. Neuropsychopharmacology22: 108–124.
37.
MarkopoulouKPapadopoulosAJuruenaMF. (2009) The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology34: 19–26.
38.
NishiMKawataM (2007) Dynamics of glucocorticoid receptor and mineralocorticoid receptor: implications from live cell imaging studies. Neuroendocrinology85: 186–192.
39.
O’KeaneVDinanTGScottL. (2005) Changes in hypothalamic-pituitary-adrenal axis measures after vagus nerve stimulation therapy in chronic depression. Biol Psychiatry58: 963–968.
40.
OshimaAYamashitaSOwashiT. (2000) The differential ACTH responses to combined dexamethasone/CRH administration in major depressive and dysthymic disorders. J Psychiatr Res34: 325–328.
41.
OtteCHinkelmannKMoritzS. (2010) Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res44: 339–346.
42.
OverdiekHWMerkusFW (1987) The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact5: 273–302.
43.
PaceTWSpencerRL (2005) Disruption of mineralocorticoid receptor function increases corticosterone responding to a mild, but not moderate, psychological stressor. Am J Physiol Endocrinol Metab288: E1082–E1088.
44.
ParianteCMPapadopoulosASPoonL. (2002) A novel prednisolone suppression test for the hypothalamic-pituitary- adrenal axis. Biol Psychiatry51: 922–930.
45.
PfohlBShermanBSchlechteJ. (1985) Differences in plasma ACTH and cortisol between depressed patients and normal controls. Biol Psychiatry20: 1055–1072.
46.
ReulJMGesingADrosteS. (2000) The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur J Pharmacol405: 235–249.
47.
ReulJMHMDe KloetER (1985) Two receptor systems for corticosterone in rat brain: Microdistribution and differential occupation. Endocrinology117: 2505–2511.
48.
RibeiroSCTandonRGrunhausL. (1993) The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry150: 1618–1629.
49.
RupprechtRReulJMVan SteenselB. (1993) Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol247: 145–154.
50.
RussellGMHenleyDELeendertzJ. (2010) Glucocorticoid receptor-mediated inhibition of hypothalamic–pituitary–adrenal ultradian activity in healthy males. J Neurosci30: 6106 – 6115.
51.
SackeimHAHaskettRFMulsantBH. (2001) Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA285: 1299–1307.
52.
SchuetzEGBrimerCSchuetzJD (1998) Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol Pharmacol54: 1113–1117.
53.
SpencerRLKimPJKalmanBA. (1998) Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology139: 2718–2726.
54.
ThaseMERushAJ (1997) When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry58 (Suppl. 13) :23–29.
55.
WatsonSGallagherPDel-EstalD. (2002) Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol Med32: 1021–1028.
56.
WellhoenerPBornJFehmHL. (2004) Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. J Clin Endocrinol Metab89: 5048–5052.
57.
WilliamsJBW (1988) Structured Interview Guide for the Hamilton-Depression And Anxiety Scales (SIGH-AD). New York: New York State Psychiatric Institute.
58.
YoungAHGallagherPWatsonS. (2004) Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology29: 1538–1545.
59.
YoungEALopezJFMurphy-WeinbergV. (1998) The role of mineralocorticoid receptors in hypothalamic-pituitary- adrenal axis regulation in humans. J Clin Endocrinol Metab83: 3339–3345.
60.
YoungEALopezJFMurphy-WeinbergV. (2003) Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry60: 24–28.
61.
ZhouSFXueCCYuXQ. (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit29: 687–710.
